| References: |
PD-0325901, a MEK inhibitor, is an orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. MEK inhibitor PD325901, a derivative of MEK inhibitor CI-1040, selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). For the detailed information about the solubility of PD0325901 (PD325901) in water, the solubility of PD0325901 (PD325901) in DMSO, the solubility of PD0325901 (PD325901) in PBS buffer, the animal experiment（test） of PD0325901 (PD325901),the in vivo,in vitro and clinical trial test of PD0325901 (PD325901),the cell experiment（test） of PD0325901 (PD325901),the IC50, EC50 and Affinity of PD0325901 (PD325901), please contact DC Chemicals. |
